Clinical trials: Treatment-Resistant Depression
Major Depressive Disorder, Treatment Resistant Depression
An Evaluation of AXS-05 for the Treatment of TRD in Treatment-Adherent Patients
The TARGET study is an active-controlled evaluation of AXS-05 compared to bupropion in patients with treatment-resistant major depressive disorder (MDD) who are adherent to study drug.
- Trial name
- TARGET (NCT04971291)
- Testing
- AXS-05, Bupropion SR
- Where
- United States
- Volunteers
- 312 people
- Sponsor
- Axsome Therapeutics, Inc.
Treatment Resistant Depressive Disorder
A Study to Evaluate the Safety and Efficacy of Intranasal Esketamine in Treatment-resistant Depression
The purpose of this study is to assess the efficacy and dose response of intranasal esketamine (Panel A: 28 mg, 56 mg, and 84 mg and Panel B: 14 mg and 56 mg) compared with placebo in improving depressive symptoms in participants…
- Trial name
- SYNAPSE (NCT01998958)
- Testing
- Esketamine 14 mg, Esketamine 28 mg, Esketamine 56 mg
- Where
- 25 sites in United States, Belgium and 1 more
- Volunteers
- 108 people
- Sponsor
- Janssen Research & Development, LLC
Depression
Brain Activity Changes and Treatment Response in Depressed People Who Are Receiving Antidepressant Medication
This study will examine how brain activity is affected by antidepressant treatment and how changes in brain activity relate to treatment response in people with depression.
- Trial name
- NCT00375843
- Testing
- Escitalopram, Sertraline
- Where
- 3 sites in United States
- Volunteers
- 118 people
- Sponsor
- National Institute of Mental Health (NIMH)
Treatment Resistant Depression
BPL-003 Efficacy and Safety in Treatment Resistant Depression
This is a Phase 2 study randomized, quadruple-masked, multi-center trial with an open-label extension (OLE), designed to investigate the efficacy and safety of BPL-003 in patients with treatment resistant depression (TRD).
- Trial name
- NCT05870540
- Testing
- BPL-003
- Where
- 42 sites in United States, Australia and 4 more
- Volunteers
- 196 people
- Sponsor
- Beckley Psytech Limited
Major Depressive Disorder (MDD), Treatment Resistant Depression (TRD)
Feasibility Trial of Exercise as a Priming Strategy for rTMS Treatment in Difficult-to-Treat Depression
The goal of this study is to collect feasibility data on combining structured exercise aimed to improve physical fitness, and intermittent TBS (iTBS) in treating individuals diagnosed with difficult-to-treat depression who are…
- Trial name
- NCT06773949
- Testing
- Theta burst stimulation
- Where
- Canada
- Volunteers
- 20 people
- Sponsor
- The Royal Ottawa Mental Health Centre
Major Depressive Disorder
Ketamine Versus Placebo for Treatment Resistant Major Depressive Disorder
Ketamine infusions resulted in an acute reduction in global depression scores and in severity of suicidal ideation. The investigators therefore plan to investigate the feasibility and efficacy of repeated intravenous…
- Trial name
- NCT01667926
- Testing
- Ketamine
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- Massachusetts General Hospital
Depression
Fermented Milk Product With Probiotic and Its Impact on Mood of Patients With Treatment Resistant Depression
This study aims to assess the impact of a chronic dietary intervention (8 weeks) with probiotics, specifically Fermented Milk Product with Probiotic (FMPP), on the mood of individuals with Major Depressive Disorder (MDD)…
- Trial name
- NCT03317678
- Testing
- BioKefir, Non-fermented milk
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Rush University Medical Center
Major Depressive Disorder
Sumor as Adjuvant Therapy in Treatment-resistant Major Depression
Sumor is a food supplement that combines the main coenzymes of the S-Adenosyl methionine (SAMe) cycle, namely vitamins B6, B12 and folate, with SAMe and betaine.
- Trial name
- SUSCA (NCT04832178)
- Testing
- SUMOR
- Where
- Italy
- Volunteers
- 102 people
- Sponsor
- Azienda Ospedaliero-Universitaria Careggi
Transcranial Magnetic Stimulation, Repetitive, Depression - Major Depressive Disorder
Effect of Theta-burst rTMS Therapy on the Clinical and Cognitive Symptoms of Patients With Therapy Resistant Depression and Response Prediction With Neuroimaging Methods.
The primary aim of the study is to find the combination of neuroimaging-related markers, demographics, and clinical characteristics that predict the response of patients with therapy-resistant depression to theta-burst rTMS…
- Trial name
- TMS-DEP-2024 (NCT07207239)
- Testing
- repetative Transcranial Magnetic Stimulation (rTMS), theta-burst protocol
- Where
- Hungary
- Volunteers
- 54 people
- Sponsor
- Semmelweis University
Treatment Resistant Depression
Development of Neuro-Navigated Transcranial Magnetic Stimulation (TMS) Using MRI
Healthy controls (HC) will be studied once to provide data needed to validate the virtual neuro-navigation system. All subjects will undergo a single MRI session and will then participate in an on-line neuro-navigation session in…
- Trial name
- NCT05598931
- Testing
- Transcranial Magnetic Stimulation
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Soterix Medical
Treatment Resistant Depression, Major Depressive Disorder
Stellate Ganglion Block for Major Depressive Disorder.
This is a feasibility study, to investigate a new treatment option for major depressive disorders by performing a Stellate Ganglion Block (SGB).
- Trial name
- NCT04727229
- Testing
- Bupivacaine Hydrochloride, Normal Saline
- Where
- Canada
- Volunteers
- 10 people
- Sponsor
- Unity Health Toronto
Major Depressive Disorder
Transcranial Direct Current Stimulation as an Augmenting Intervention for Major Depression
Transcranial direct current stimulation (tDCS) is a noninvasive method to activate or de-activate neurons in superficial regions of the brain through the induction of weak electric currents in the brain tissue delivered by two…
- Trial name
- NCT01450150
- Testing
- Transcranial Direct Current Stimulation
- Where
- Canada
- Volunteers
- 30 people
- Sponsor
- Douglas Mental Health University Institute
Treatment Resistant Depression
Cannabidiol for Treatment Resistant Depression
With this study, the investigators will address the following scientific aims: 1. Demonstrate the antidepressant effects of CBD in human adults with treatment refractory MDD as measured by standard rating scales. 2.
- Trial name
- CBD (NCT04732169)
- Testing
- Active study drug ( oral CBD)
- Where
- United States
- Sponsor
- University of Alabama at Birmingham
Major Depression
Antidepressant Effects of Ayahuasca: a Randomized Placebo Controlled Trial in Treatment Resistant Depression
The purpose of the present trial is to test the efficacy of Ayahuasca in treatment-resistant depression. Ayahuasca is a decoction of two plants, long used by Amazonian Amerindians.
- Trial name
- NCT02914769
- Testing
- Ayahuasca
- Where
- Brazil
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Universidade Federal do Rio Grande do Norte
Depressive Disorder, Treatment-Resistant
A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression
The purpose of this study is to assess the efficacy of intranasal esketamine plus an oral antidepressant compared with an oral antidepressant (active comparator) plus intranasal placebo in delaying relapse of depressive symptoms…
- Trial name
- SUSTAIN-1 (NCT02493868)
- Testing
- Esketamine, Duloxetine (Oral Antidepressant), Escitalopram (Oral antidepressant)
- Where
- 155 sites in United States, Belgium and 13 more
- Volunteers
- 719 people
- Sponsor
- Janssen Research & Development, LLC
Refractory Depression, Anxiety Disorders
Near-Infrared Laser Stimulation for Various Neurological Conditions
The study will evaluate the safety and feasibility of near infrared therapy as an intervention for patients with refractory depression, anxiety, neurodegenerative disease, and traumatic brain injury.
- Conditions
- Refractory Depression, Anxiety Disorders, Neurodegenerative Diseases, Traumatic Brain Injury
- Trial name
- NCT04489082
- Testing
- Near Infrared Laser Stimulation
- Where
- United States
- Volunteers
- 400 people
- Sponsor
- Neurological Associates of West Los Angeles
Depression, Depressive Disorder, Treatment-Resistant
Improving Brain Stimulation Through Imaging
There are two protocols, one involving rTMS therapy in people with treatment resistant depression and one involving tDCS in people with stress from the COVID 19 pandemic.
- Conditions
- Depression, Depressive Disorder, Treatment-Resistant, COVID Stress, PTSD - Post Traumatic Stress Disorder
- Trial name
- IBSI (NCT03851380)
- Testing
- Psychological / Functional Assessment, Structural and Functional MRI, Transcranial Magnetic Brain Stimulation and MR Image Guidance
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- VA Office of Research and Development
Depressive Disorder, Treatment-Resistant
A Study of Esketamine Nasal Spray Plus a New Standard-of-care Oral Antidepressant or Placebo Nasal Spray Plus a New Standard-of-care Oral Antidepressant in Adult and Elderly Participants With Treatment-resistant Depression
The purpose of this study is to evaluate the efficacy of treating participants with treatment-resistant depression (TRD) who have failed at least 2 (and no more than 6) prior antidepressant (AD) treatments in the current moderate…
- Trial name
- NCT03852160
- Testing
- Esketamine 28 mg, Esketamine 56 mg, Esketamine 84 mg
- Sponsor
- Janssen-Cilag International NV
Treatment Resistant Depression, Chronic Pain
Treatment With Psilocybin for Chronic Neuropathic Pain and Depression (TRANSCEND)
Psilocybin, the chemical component of "magic mushrooms", has been administered with psychotherapy in several randomized clinical trials (RCTs) showing large and sustained antidepressant effects.
- Trial name
- TRANSCEND (NCT06518720)
- Testing
- Psilocybin 25 mg
- Where
- Canada
- Volunteers
- 16 people
- Sponsor
- Centre for Addiction and Mental Health
Treatment-Resistant Major Depressive Disorder
Avatar Therapy in Virtual Reality for Treatment-Resistant Major Depressive Disorder: A Pilot Study
This pilot clinical trial aimed to evaluate the short-term efficacy of Avatar therapy for treatment-resistant major depressive disorder
- Trial name
- NCT07112261
- Testing
- Avatar Therapy
- Where
- Canada
- Volunteers
- 15 people
- Sponsor
- Ciusss de L'Est de l'Île de Montréal